Integration of cancer-related genetic landscape of Eph receptors and ephrins with proteomics identifies a crosstalk between EPHB6 and EGFR.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
25 07 2023
Historique:
received: 07 12 2022
revised: 05 05 2023
accepted: 05 06 2023
medline: 31 7 2023
pubmed: 1 7 2023
entrez: 1 7 2023
Statut: ppublish

Résumé

Eph receptors and their ephrin ligands are viewed as promising targets for cancer treatment; however, targeting them is hindered by their context-dependent functionalities. To circumvent this, we explore molecular landscapes underlying their pro- and anti-malignant activities. Using unbiased bioinformatics approaches, we construct a cancer-related network of genetic interactions (GIs) of all Ephs and ephrins to assist in their therapeutic manipulation. We also apply genetic screening and BioID proteomics and integrate them with machine learning approaches to select the most relevant GIs of one Eph receptor, EPHB6. This identifies a crosstalk between EPHB6 and EGFR, and further experiments confirm the ability of EPHB6 to modulate EGFR signaling, enhancing the proliferation of cancer cells and tumor development. Taken together, our observations show EPHB6 involvement in EGFR action, suggesting its targeting might be beneficial in EGFR-dependent tumors, and confirm that the Eph family genetic interactome presented here can be effectively exploited in developing cancer treatment approaches.

Identifiants

pubmed: 37392382
pii: S2211-1247(23)00681-2
doi: 10.1016/j.celrep.2023.112670
pii:
doi:

Substances chimiques

Ephrins 0
Receptors, Eph Family EC 2.7.10.1
ErbB Receptors EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

112670

Subventions

Organisme : CIHR
ID : PJT-156309
Pays : Canada
Organisme : CIHR
ID : PJT-156401
Pays : Canada

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Glinton Hanover (G)

Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Royal University Hospital, Room 2841, 103 Hospital Drive, Saskatoon, SK S7N 0W8, Canada; Department of Biochemistry, Microbiology and Immunology, University of Saskatchewan, GA20 Health Sciences, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canada.

Frederick S Vizeacoumar (FS)

Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Royal University Hospital, Room 2841, 103 Hospital Drive, Saskatoon, SK S7N 0W8, Canada.

Sara L Banerjee (SL)

Department of Molecular Biology, Medical Biochemistry and Pathology, PROTEO and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Quebec-Université Laval, Division Oncologie, 9 Rue McMahon, Québec, QC G1R 3S3, Canada.

Raveena Nair (R)

Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Royal University Hospital, Room 2841, 103 Hospital Drive, Saskatoon, SK S7N 0W8, Canada; Department of Biochemistry, Microbiology and Immunology, University of Saskatchewan, GA20 Health Sciences, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canada.

Renuka Dahiya (R)

Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Royal University Hospital, Room 2841, 103 Hospital Drive, Saskatoon, SK S7N 0W8, Canada.

Ana I Osornio-Hernandez (AI)

Department of Molecular Biology, Medical Biochemistry and Pathology, PROTEO and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Quebec-Université Laval, Division Oncologie, 9 Rue McMahon, Québec, QC G1R 3S3, Canada.

Alain Morejon Morales (AM)

Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Royal University Hospital, Room 2841, 103 Hospital Drive, Saskatoon, SK S7N 0W8, Canada; Department of Biochemistry, Microbiology and Immunology, University of Saskatchewan, GA20 Health Sciences, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canada.

Tanya Freywald (T)

Cancer Research, Saskatchewan Cancer Agency and Division of Oncology, University of Saskatchewan, 4D30.2 Health Sciences Building, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canada.

Juha P Himanen (JP)

Department of Biochemistry, University of Turku, 20500 Turku, Finland.

Behzad M Toosi (BM)

Department of Small Animal Clinical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, 52 Campus Drive, Saskatoon, SK S7N 5B4, Canada.

Nicolas Bisson (N)

Department of Molecular Biology, Medical Biochemistry and Pathology, PROTEO and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Quebec-Université Laval, Division Oncologie, 9 Rue McMahon, Québec, QC G1R 3S3, Canada. Electronic address: nick.bisson@crchudequebec.ulaval.ca.

Franco J Vizeacoumar (FJ)

Cancer Research, Saskatchewan Cancer Agency and Division of Oncology, University of Saskatchewan, 4D30.2 Health Sciences Building, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canada. Electronic address: franco.vizeacoumar@usask.ca.

Andrew Freywald (A)

Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Royal University Hospital, Room 2841, 103 Hospital Drive, Saskatoon, SK S7N 0W8, Canada. Electronic address: andrew.freywald@usask.ca.

Articles similaires

Humans Male Female Health Knowledge, Attitudes, Practice Middle Aged
Humans Neoplasms Male Female Middle Aged
Humans Middle Aged Female Male Surveys and Questionnaires
Humans Receptors, Antigen, T-Cell Proto-Oncogene Proteins p21(ras) Pancreatic Neoplasms T-Lymphocytes

Classifications MeSH